January 10, 2018 / 1:43 PM / Updated 25 minutes ago BRIEF-Moleculin Expands Leukemia Development Portfolio With Immuno-Stimulating Stat3 Inhibitor Reuters Staff 
Jan 10 (Reuters) - Moleculin Biotech Inc: 
* MOLECULIN EXPANDS LEUKEMIA DEVELOPMENT PORTFOLIO WITH IMMUNO-STIMULATING STAT3 INHIBITOR 
* MOLECULIN BIOTECH INC - EXPANDED COMPANYâ€˜S DEVELOPMENT PIPELINE FOR TREATMENT OF ACUTE MYELOID LEUKEMIA WITH AN IMMUNO-STIMULATING STAT3 INHIBITOR Source text for Eikon: Further company coverage: